Skip to main content
OpenTrials
Completed

NCT Number: NCT07627074

Weight Loss in Adults Using Semaglutide (Real-world Study)

The purpose of the study is to assess the weight loss in participants treated with commercially available semaglutide according to routine clinical practice at the discretion of the treating physician.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Overweight Body Weight Nutrition Disorders Nutritional and Metabolic Diseases Obesity Overnutrition Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Novo Nordisk Investigational Site, London, United Kingdom

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Initiation of semaglutide for weight management during the study period.
  • Age more than or equal to (≥) 18 at treatment initiation
  • Baseline body mass index (BMI) ≥27 and less than (<) 30 kilogram per meter square (kg/m^2) with at least one weight-related comorbidity, or BMI ≥30 kg/m^2.
  • Other inclusion criteria as defined in the protocol are applicable.

Exclusion criteria

  • Prior use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) based medication or other obesity management medication (OMMs).
  • Bariatric surgery at baseline.
  • Diabetes at baseline.
  • Pregnancy at baseline.

Treatment and study plan

semaglutide

Drug

This is a retrospective, non-interventional study; therefore, no intervention was administered as part of the study.

Primary outcomes

  1. Change in body weight

    Time frame: From index date (day 0) to week 68 (day 476)

    Measured as kilogram (kg)

  2. Change in body weight

    Time frame: From index date (day 0) to week 68 (day 476)

    Measured as percentage (%)

  3. Proportion of individuals achieving a clinically meaningful weight loss

    Time frame: From index date (day 0) to week 68 (day 476)

    Binary (yes/no): estimated ≥5% reduction from baseline body weight

Sponsors and collaborators

Lead sponsor

Novo Nordisk A/S

Industry

Registry information

Official study title

Real-world Weight Outcomes in Adults Treated With Semaglutide s.c. 1.0 mg or 1.7 mg for Weight Management: a Non-interventional Cohort Study

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Jun 4, 2026
Registry last updated
Sep 4, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.